A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (NCT05327647)
A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
Who can join: Review the eligibility criteria below.
Location: London Health Sciences Centre — London, Ontario
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- London Health Sciences Centre — London, Ontario
- University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario
- Centre intégré de santé et services sociaux de Chaudière Appalaches — Lévis, Quebec
- Centre Hospitalier de l'Université De Montréal_CHUM — Montreal, Quebec
- McGill University Health Centre_CUSM — Montreal, Quebec
- CHU de Québec-Université Laval — Québec, Quebec
- CIUSSS de l'Estrie - CHUS — Sherbrooke, Quebec
📞 Contact the Study Coordinator
Phone: (418) 525-4444
Email: paul.toren@crchudequebec.ulaval.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Muscle Invasive Bladder Cancer
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer — Birmingham, Alabama
- Study of CG0070 After Transurethral Resection in Patients With IR NMIBC — Tampa, Florida
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Tucson, Arizona
- Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention — Dallas, Texas
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer — Tampa, Florida
- Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment — Basking Ridge, New Jersey
Explore by condition: All Non-Muscle Invasive Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.